Anixa Biosciences Announces Abstract Accepted for Presentation at the 34th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2019)
SAN JOSE, Calif., Oct. 22, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body's immune system to fight cancer, today announced the acceptance of an abstract at the 34th Annual Meeting of the Society for Immunotherapy of Cancer (SITC). A poster presentation will include data from ongoing studies utilizing Cchek™, the company's artificial intelligence (AI) driven cancer detection technology.
The SITC meeting is being held November 6 – 10, 2019 in National Harbor, MD. Cutting-edge research will be presented by experts in the field of applied cancer immunotherapy and translational research. The meeting will be attended by both U.S. and international researchers, regulators, and healthcare professionals who are involved in cancer research and clinical care.
Poster presentation details are as follows:
Title: Early detection of breast cancer (BCa) through MDSC and lymphocyte immunophenotyping: from manual gating to pattern recognition neural networks
Authors: George A. Dominguez, Ph.D.; John Roop; Alex Polo; Anthony J. Campisi; Dmitry I. Gabrilovich, MD, Ph.D.; Amit Kumar, Ph.D.
Poster Number: P11
Location: Gaylord National Hotel & Convention Center; Poster Hall: Prince George AB
Date and Time: Friday, November 8, 2019 (12:30 – 2:00 PM ET and 6:30 – 8:00 PM ET)
To receive a copy of the presentation, please email your request to SITCfirstname.lastname@example.org starting November 10, 2019 and include your name, title, and contact information.
Cchek™ is an early cancer detection technology, which measures a patient's immunological response to a malignancy by analyzing immune system cells in peripheral blood. The goal is to utilize the technology to determine a patient's cancer status from a simple blood draw, eliminating the need for a biopsy, which can be an expensive, painful and invasive procedure. Further, conventional methods using current cancer screening tests often lack accuracy and reliability. Anixa's orthogonal approach using flow cytometry coupled with artificial intelligence provides an alternative method with greater affordability, efficacy and efficiency. To date, Anixa has successfully used Cchek™ to detect the presence of 20 different cancers including lung, colon, breast and prostate. The robust cancer detection performance of Cchek™ makes it a platform from which multiple cancer diagnostic tests may be developed. The first such test, a prostate cancer confirmation test, is slated for commercial launch by the end of 2019.
About Anixa Biosciences, Inc.
Anixa is a publicly-traded biotechnology company focused on harnessing the body's immune system in the fight against cancer. Anixa's therapeutic portfolio includes a cancer vaccine technology focused on the immunization against α-Lactalbumin to prevent triple negative breast cancer (TNBC), as well as a cancer immunotherapy program which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology. The company's diagnostic portfolio consists of Cchek™, a liquid biopsy technology for early detection of solid tumors based on the body's immune response to the presence of a malignancy. Anixa continually examines emerging technologies in complementary fields for further development and commercialization. Additional information is available at www.anixa.com.
Forward-Looking Statements: Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.
Sharen Tilman (Investors)
Johanna Bennett (Media)
View original content to download multimedia:http://www.prnewswire.com/news-releases/anixa-biosciences-announces-abstract-accepted-for-presentation-at-the-34th-annual-meeting-of-the-society-for-immunotherapy-of-cancer-sitc-2019-300942444.html
SOURCE Anixa Biosciences, Inc.
Released October 22, 2019
Sign up for email Updates
Be The First to Receive Breaking NewsSign Up Now